Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Halabi

Showing results (121-130 of 282) with videos related to

Pageof 29
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2014
Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancerSusan Halabi, Chen-Yen Lin, W Kevin Kelly, et al.
International Journal of Radiation Oncology, Biology, Physics|November 27, 2007
Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 studyAnthony V D'Amico, Susan Halabi, Clare Tempany, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 21, 2003
No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North CarolinaJohnathan M Lancaster, Robert M Wenham, Susan Halabi, et al.
Urologic Oncology|September 17, 2019
Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancerDaniel J George, Susan Halabi, Patrick Healy, et al.
Urology|February 23, 2008
p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682)Anthony V D'Amico, Susan Halabi, Robin Vollmer, et al.
The Prostate|November 19, 2016
Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH TrialAndrew J Armstrong, Michael S Humeniuk, Patrick Healy, et al.
Cancer|December 20, 2011
Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782J Paul Monk, Susan Halabi, Joel Picus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2003
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancerSusan Halabi, Eric J Small, Philip W Kantoff, et al.
Journal of the National Cancer Institute|February 16, 2013
Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapyAndrea B Apolo, Irina Ostrovnaya, Susan Halabi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2004
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583)Eric J Small, Susan Halabi, Nancy A Dawson, et al.
Pageof 29

Showing results (121-130 of 282) with videos related to

Sort By:
Pageof 29
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2014
Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancerSusan Halabi, Chen-Yen Lin, W Kevin Kelly, et al.
International Journal of Radiation Oncology, Biology, Physics|November 27, 2007
Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 studyAnthony V D'Amico, Susan Halabi, Clare Tempany, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 21, 2003
No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North CarolinaJohnathan M Lancaster, Robert M Wenham, Susan Halabi, et al.
Urologic Oncology|September 17, 2019
Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancerDaniel J George, Susan Halabi, Patrick Healy, et al.
Urology|February 23, 2008
p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682)Anthony V D'Amico, Susan Halabi, Robin Vollmer, et al.
The Prostate|November 19, 2016
Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH TrialAndrew J Armstrong, Michael S Humeniuk, Patrick Healy, et al.
Cancer|December 20, 2011
Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782J Paul Monk, Susan Halabi, Joel Picus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2003
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancerSusan Halabi, Eric J Small, Philip W Kantoff, et al.
Journal of the National Cancer Institute|February 16, 2013
Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapyAndrea B Apolo, Irina Ostrovnaya, Susan Halabi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2004
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583)Eric J Small, Susan Halabi, Nancy A Dawson, et al.
Pageof 29